Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Korlym (Mifepristone) for Treatment of Endogenous Cushing’s Syndrome

Drug Name (Brand / Generic)

Korlym / mifepristone

Developed by

Corcept Therapeutics

Therapy Class

Cortisol receptor blocker

Product Description

Glucocorticoid antagonist

Current Indication

Endogenous Cushing’s syndrome

Market Sector


Development Status

Approved in the US

Free download worth over $5000
Download our 2019 Technology, Media and Telecoms Predictions Report

Worth up to $5,850

In this report, we look at the 30 big tech themes for 2019, identifying winners and losers for each theme. This report will impact all industries helping:

  • CEOs/Senior Staff: in all industries understand the disruptive threats to their competitive landscape
  • Investors: Helps fund managers focus their time on the most interesting investment opportunities in global TM

Go Top